Pulmonary embolism (PE) remains a major cause of cardiovascular morbidity and mortality worldwide. It occurs when thrombotic material—most often ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Researchers have found in a new study that the novel Lesifter device shows encouraging early efficacy and a favorable safety profile in reducing stroke risk among patients with atrial ...

Tom Nolan reviews this week’s research An editorial about D-dimers likens the endlessly talked about blood test to a fine wine. It’s nothing to do with its taste (I find it a bit claggy) or cost, but ...

Dutch trial establishes feasibility of screening approach in routine specialty care ...

Our extensive research on the United States Anticoagulation Therapy (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, inv ...

The company outlined progress on its anticoagulation pipeline, including its HIT program VLX-1005, at a Lytham Partners ...

Detailed price information for Cadrenal Therapeutics Inc (CVKD-Q) from The Globe and Mail including charting and trades.

Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation with a stent planted at least 1 year prior, oral anticoagulation ...

Oral anticoagulation was associated with a reduced risk for ischemic stroke and increased risk for intracranial hemorrhage in patients with atrial fibrillation and prior intracranial hemorrhage. Oral ...